OptraSCAN®, the leading end-to-end digital pathology solution provider announces the introduction of OnDemand Digital Pathology® solution to meet today's need for the complete digital transformation of pathology laboratories in North America.
OptraSCAN’s mission to enable pathology slide digitization at fractional costs is eventually resulting into higher market demand for digital pathology applications. This partnership with Paige will facilitate adoption of digital infrastructure for global clinical and molecular pathology community in an efficient way.”
SAN JOSE, Calif., May 24, 2022 / -- OptraSCAN®, the leading end-to-end digital pathology solution provider, announced its digital pathology scanner OS-SiA has been granted US patent - No 2020/0334814 A1 by the United States Patent and Trademark Office.
OptraSCAN® is eliminating the barriers to adopting digital pathology no matter the size of the pathology lab, the lab's throughput or location. Our affordable and easy to implement solutions will maximize your return on investment. OptraSCAN will be a partner to help improve the performance of your pathology services.
OptraSCAN’s Intelligent Tool CytoSiA – To Advance Cytology Screening Through Unmatched Image Quality And Artificial Intelligence Based Image Analysis Solution
OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use.
Satisfied Users & 
Approved Press Releases
